title: Evaluation for Peritoneal Injury at an Early Stage Using Dual Macromolecular Markers.
abstract: Long-term peritoneal dialysis (PD) frequently produces morphological and functional changes of the peritoneum, making continuation of PD difficult. Therefore, it is necessary to evaluate peritoneal injury at an early stage and develop appropriate therapies. The aims of the present study were to evaluate peritoneal injury at an early stage and assess a drug for prevention of peritoneal injury using our previously developed novel evaluation method. Peritoneal injury was induced in model animals by intraperitoneal injection of methylglyoxal (MGO) for 1 to 5 consecutive days or chlorhexidine digluconate (CG) for 1 to 14 consecutive days. Tetramethylrhodamine-dextran (RD)-10 and fluorescein isothiocyanate-dextran (FD)-2000 were then injected into the peritoneal cavity and recovered after 120 min to evaluate peritoneal injury. The ratio of the concentration of RD-10 to FD-2000 (RD-10/FD-2000 ratio) significantly decreased in animals that had been treated with MGO or CG for 1 d. Moreover, the RD-10/FD-2000 ratio significantly increased in CG- and thalidomide-treated animals. The RD-10/FD-2000 ratio can be used to evaluate peritoneal injury at an early stage and assess the drug efficacy of thalidomide for prevention of peritoneal injury. This study will contribute to the development of therapeutic treatments for peritoneal injury.
authors.affiliation: Graduate School of Biomedical Sciences, Nagasaki University.
authors.forename: Haruna
authors.initials: H
authors.lastname: Hirata
authors.forename: Shintaro
authors.initials: S
authors.lastname: Fumoto
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Mikiro
authors.initials: M
authors.lastname: Nakashima
authors.forename: Morio
authors.initials: M
authors.lastname: Nakayama
authors.forename: Koyo
authors.initials: K
authors.lastname: Nishida
mesh_terms: D000818:Animals; D002710:Chlorhexidine / Q000031:analogs & derivatives; D003911:Dextrans / Q000494:pharmacology*; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives / Q000494:pharmacology*; D005456:Fluorescent Dyes / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D010530:Peritoneal Dialysis; D010532:Peritoneal Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D010537:Peritoneum / Q000293:injuries* / Q000473:pathology; D011765:Pyruvaldehyde; D017208:Rats, Wistar; D012235:Rhodamines / Q000494:pharmacology*; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D003911:Dextrans; D005456:Fluorescent Dyes; C067661:Fluoro-Ruby; D012235:Rhodamines; D013792:Thalidomide; D011765:Pyruvaldehyde; D016650:Fluorescein-5-isothiocyanate; C010882:chlorhexidine gluconate; D002710:Chlorhexidine